Correction of psychoemotional status using succinate-containing drugs in comorbid patients with primary hypothyroidism: outlooks

Objective: to assess sanogenetic effects of combination treatment with remaxol and mexidol on the psychoemotional state and quality of life in comorbid patients with primary hypothyroidism. Materials and methods. This study included 111 patients with primary hypothyroidism and various hepatobiliopancreatic disorders. All patients underwent laboratory testing and ultrasound examination. Participants in the experimental group (n = 91) received levothyroxine sodium, remaxol, and mexidol, whereas participants in the control group (n = 20) received levothyroxine sodium alone. We evaluated patients' quality of life using the SF-36 questionnaire, presence and severity of depression using Zung self-rating depression scale, situational and personal anxiety using the Spielberger-Khanin's test, and aggression level using the Buss-Durkee Hostility Inventory. All examinations were performed prior to treatment initiation and after two months of treatment. Results. Patients with decompensated hypothyroidism had higher personal anxiety and lower quality of life than those with compensated hypothyroidism. Longer duration of hypothyroidism was associated with higher levels of depression, lower pain intensity, and role functioning caused by the emotional state. Patients who received succinate-containing drugs demonstrated a decrease in depression severity, situational and personal anxiety, as well as improved quality of life after treatment. Conclusion. The psychoemotional state and quality of life of patients with primary hypothyroidism and hepatobiliopancreatic disorders primarily depend on the duration of hypothyroidism and efficacy of its control. The use of succinate-containing drugs in addition to hormone replacement therapy improves the psychoemotional status and quality of life of patients with primary hypothyroidism.